Want to join the conversation?
Pharmaceutical company $LLY & Boehringer Ingelheim Pharmaceuticals said that FDA granted approval for Basaglar (insulin glargine injection) to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. As per the settlement agreement with Sanofi, the drug will be available in the US starting Dec. 15, 2016.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.